ABBVie (NYSE: ABBV) today announced top-line results from the Phase 3b Heads Up study showing that upadacitinib (30 mg, once daily) achieved superiority to dupilumab (300 mg, every other week) for the primary endpoint, the proportion of patients with at least a 75 percent improvement in the Eczema Area Severity Index (EASI 75) at week 16, in adults with moderate to severe atopic dermatitis. 1 Of patients treated with upadacitinib, 71 percent achieved EASI 75 at week 16 compared to 61 percent of dupilumab-treated patients (p=0.006) Continue reading →

This article was originally published here Eur J Dermatol. Continue reading →

Sponsored content by Memorial Regional Health Colorado winters arent easy on the skin. The air outside is cold, dry and lacking in humidity, which can cause skin irritation and dehydration. People also tend to do things to stay warm inside, such as run the heat in their homes or crank up the hot water in the shower. Continue reading →

The recent document on Atopic Eczema Treatment market offers insights about the workings of this business sphere with respect to the key drivers, restraints, and opportunities that will influence the industry growth during forecast period. Continue reading →

Iryna VeklichGetty Images Jojoba oil is derived from the cold-pressed seeds of simmondsia chinensis, a shrub native to Mexico and parts of the American Southwest. Continue reading →